2022
DOI: 10.1007/s12098-022-04254-5
|View full text |Cite
|
Sign up to set email alerts
|

Initial Immunomodulation and Outcome of Children with Multisystem Inflammatory Syndrome Related to COVID-19: A Multisite Study from India

Abstract: Objective To determine the outcomes in children with MIS-C receiving different immunomodulatory treatment. Methods In this multicentric, retrospective cohort study, data regarding treatment and outcomes of children meeting the WHO case definition for MIS-C, were collected. The primary composite outcome was the requirement of vasoactive/inotropic support on day 2 or beyond or need of mechanical ventilation on day 2 or beyond after initiation of immunomodulatory treatment or death during hospitalization in the t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
5
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 7 publications
(5 citation statements)
references
References 9 publications
0
5
0
Order By: Relevance
“… 24 Six large observational studies have assessed effectiveness of glucocorticoid monotherapy, intravenous immunoglobulins, or intravenous immunoglobulins plus glucocorticoids. 12 , 13 , 14 , 15 , 23 , 25 Son and colleagues 13 compared 103 propensity-matched patients treated with intravenous immunoglobulins plus glucocorticoids with 103 patients treated with intravenous immunoglobulins alone. Initial treatment with glucocorticoids and intravenous immunoglobulins was associated with lower risk of the composite outcome of cardiovascular dysfunction on or after day 2 than intravenous immunoglobulins alone (17% vs 31%, risk ratio 0·56, 95% CI 0·34–0·94).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“… 24 Six large observational studies have assessed effectiveness of glucocorticoid monotherapy, intravenous immunoglobulins, or intravenous immunoglobulins plus glucocorticoids. 12 , 13 , 14 , 15 , 23 , 25 Son and colleagues 13 compared 103 propensity-matched patients treated with intravenous immunoglobulins plus glucocorticoids with 103 patients treated with intravenous immunoglobulins alone. Initial treatment with glucocorticoids and intravenous immunoglobulins was associated with lower risk of the composite outcome of cardiovascular dysfunction on or after day 2 than intravenous immunoglobulins alone (17% vs 31%, risk ratio 0·56, 95% CI 0·34–0·94).…”
Section: Discussionmentioning
confidence: 99%
“…However, when comparing hospital length of stay between these groups in mixed linear regression analyses, no significant difference was observed after adjusting for confounding variables. Bagri and colleagues 25 showed in their propensity score matched analysis that patients treated with glucocorticoids (n=45) versus intravenous immunoglobulins combined with glucocorticoids (n=84) did not differ in relation to the need of inotropes or respiratory support 2 days and later after treatment initiation.…”
Section: Discussionmentioning
confidence: 99%
“…MIS-C is itself a serious complication of COVID-19 [19]. CVS is the most common sequelae of MIS-C. Like Kawasaki disease (KD), coronary artery aneurysms and dilation have been documented in 20%-25% of children [20].…”
Section: Sequelae Of Multisystem Inflammatory Syndrome In Children (M...mentioning
confidence: 99%
“…The optimal treatment regime is still under debate because of scarce and conflicting data. For instance, no differences in death or need for vasoactive support or mechanical ventilation was observed between IVIG alone, glucocorticoids alone, and IVIG with glucocorticoid treatment groups [98,99]. However, IVIG with glucocorticoid was shown to be superior to IVIG alone and glucocorticoid alone in reducing ICU duration, but not the overall length of hospital stay [100].…”
Section: Treatmentmentioning
confidence: 99%